The article from the World Health Organization (WHO) Regional Office for Africa, titled “The Democratic Republic of the Congo kicks off mpox vaccination,” provides crucial information regarding the launch of the mpox vaccination campaign in the Democratic Republic of the Congo. This initiative marks a significant effort to combat the ongoing mpox outbreak and is essential for safeguarding public health.
The Democratic Republic of the Congo (DRC) launched its mpox vaccination campaign on October 5, 2024, in the eastern North Kivu province. This initiative is part of the ongoing efforts to control the mpox outbreak and save lives.
The vaccination will prioritise several groups, including health workers, frontline responders, and other at-risk groups. The campaign will subsequently expand to 11 of the most affected health zones in Equateur, North Kivu, Sankuru, South Kivu, Sud-Ubangi, and Tshopo provinces.
The country has received 265,000 doses of the MVA-BN vaccine, donated by the European Commission’s Health Emergency Preparedness and Response Authority, Gavi, the Vaccine Alliance, and the United States Government.
WHO recommends that mpox vaccination be part of a comprehensive response, which includes enhanced surveillance, community engagement, contact tracing, public health and social measures, and appropriate case management. As a result, WHO and partners are working closely with national authorities to scale up and reinforce these control measures.
More than 300 WHO experts, previously involved in polio eradication, have now joined the mpox response. With extensive field experience, they contribute to community-based and health-facility surveillance, case investigations, contact tracing, and risk communication.
WHO has supported national health authorities in various areas, including training health workers and enhancing vaccine delivery systems and infrastructure, including vaccine storage and transportation. Furthermore, community engagement and ensuring supervision for the vaccination process are also priorities. As a result, efforts are underway to address vaccine misinformation and engage with community and religious leaders.
In 2024, the DRC has reported over 30,000 laboratory-confirmed mpox cases and 990 deaths. This accounts for 90% of the cases reported in the African region this year.
Mpox vaccines are currently in short supply, especially in Africa. The MVA-BN vaccine received WHO’s prequalification in September 2024, which facilitates timely access. Moreover, WHO is collaborating with partners to establish a distribution mechanism for donated doses and direct procurements from the vaccine manufacturer.
In conclusion, the vaccination campaign is a critical step in addressing the mpox outbreak in the Democratic Republic of Congo. Furthermore, this effort is supported by a comprehensive strategy that integrates multiple public health measures and emphasizes international collaboration.
🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!
#SyenzaNews #globalhealth #healthcareInnovation
🌍 Can collaboration redefine Africa’s health landscape?
A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.
Look into the details of this transformative partnership and its implications for the future of healthcare in the region!
#SyenzaNews #globalhealth #HealthcareInnovation
🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?
A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.
Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.
#SyenzaNews #globalhealth #oncology #HealthTech
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
